Department of Cardiology, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain.
Department of Cardiology, Hospital de la Santa Creu y Sant Pau, Barcelona, Spain
Eur Heart J Acute Cardiovasc Care. 2014 Sep;3(3):229-36. doi: 10.1177/2048872614527008. Epub 2014 Mar 17.
Massive intracoronary thrombus is associated with adverse procedural results including failed aspiration and unfavourable reperfusion. In this scenario the best treatment remains unknown. We aim to evaluate the effect of low dose intracoronary thrombolysis in patients with ST-segment elevation myocardial infarction (STEMI) presenting with a large thrombus burden and failed aspiration.
In this study 30 STEMI patients with a large thrombus burden and failed manual aspiration were included in the registry. Local fibrinolysis with low dose (one-third of systemic) tenecteplase (27%) or alteplase (73%) was administered via a 6F-infusion catheter. A thrombus was qualified as large when its maximal dimension was ≥2 vessels (thrombolysis in myocardial infarction (TIMI) thrombus grade 4 and 5). Altogether 33% of patients received delayed invasive therapy (>12 h) guided by the presence of recurrent symptoms and/or ischaemia. A total of 17% of patients presented with cardiogenic shock and half of the population received glycoprotein IIb/IIIa inhibitors. A post-lysis thrombus grade 4-5 was found in just one patient. TIMI flow grade improved from 0/1 at baseline (93%) to ≥2 in most patients (97%). Blush grade 2-3 was observed in 85% and we observed a similar percentage (82%) of more than 50% ST-segment resolution. In-hospital mortality was 10% (three patients with cardiogenic shock). No major bleeding events were observed. At a median follow-up of 14 (6-35) months, only one new clinical event was reported (1 target lesion revascularization, (TLR)).
In STEMI patients with a large thrombus burden and failed manual aspiration, administration of low dose intracoronary thrombolysis is safe and reduces trhombus burden, as a result improving in epicardial flow and myocardial reperfusion.
冠状动脉内大量血栓与不良的手术结果相关,包括抽吸失败和血流灌注不良。在这种情况下,最佳治疗方法仍不清楚。我们旨在评估在 ST 段抬高型心肌梗死(STEMI)患者中,对于存在大量血栓负荷且抽吸失败的患者,给予小剂量冠状动脉内溶栓的效果。
在这项研究中,共有 30 例存在大量血栓负荷且抽吸失败的 STEMI 患者被纳入该注册研究。通过 6F 输注导管给予小剂量(全身剂量的三分之一)替奈普酶(27%)或阿替普酶(73%)进行局部溶栓。当血栓的最大尺寸≥2 个血管(心肌梗死溶栓治疗(TIMI)血栓分级 4 和 5)时,将其定性为大血栓。共有 33%的患者因症状复发和/或缺血而接受延迟的有创治疗(>12 小时)。共有 17%的患者出现心原性休克,半数患者接受了糖蛋白 IIb/IIIa 抑制剂。仅 1 例患者溶栓后血栓分级为 4-5。TIMI 血流分级从基线的 0/1(93%)提高到大多数患者(97%)的≥2。85%的患者出现 2-3 级的心肌灌注,82%的患者出现 ST 段回落超过 50%。住院死亡率为 10%(3 例心原性休克)。未观察到重大出血事件。中位随访 14 个月(6-35 个月),仅报告了 1 例新的临床事件(1 例靶病变血运重建(TLR))。
在存在大量血栓负荷且抽吸失败的 STEMI 患者中,给予小剂量冠状动脉内溶栓是安全的,可以降低血栓负荷,从而改善心外膜血流和心肌再灌注。